The aryl hydrocarbon receptor (AHR) is a ligand-activated protein that mediates the toxic actions of polycyclic aromatic and halogenated compounds. Identifying genes directly regulated by AHR is important in understanding the pathways regulated by this receptor. Here we used the techniques of chromatin immunoprecipitation and DNA microarrays (ChIP-chip) to detect AHR-bound genomic regions after 3-methylcholanthrene (3MC) treatment of T-47D human breast cancer cells. We identified 241 AHR-3MC-bound regions, and transcription factor-binding site analysis revealed a strong overrepresentation of the AHR-responsive element. Conventional ChIP confirmed recruitment of AHR to 26 regions with target gene responses to 3MC varying from activation to inhibition to having no effect. A comparison of identified AHR-3MC-bound regions with AHR-2,3,7,8-tetrchlorodibenzo-p-dioxin (TCDD)-bound regions from our previous study (Ahmed, S., Valen, E., Sandelin, A., and Matthews, J. (2009). Toxicol. Sci. 111, 254-266) revealed that 127 regions were common between the data sets. Time course ChIPs for six of the regions showed that 3MC induced gene-specific changes in histone H3 acetylation and methylation and induced differential oscillatory binding of AHR, with a periodicity between 1.5 and 2 h. Re-treatment of cells with 3MC failed to alter the oscillatory binding profiles of AHR or aryl hydrocarbon receptor nuclear translocator. Cells became responsive to 3MC but not TCDD after 24 h of exposure to 3MC, highlighting important differences in AHR responsiveness between the two ligands. Our results reveal a number of novel AHR-bound promoter regions and target genes that exhibit differential kinetic binding profiles and regulation by AHR.
The aryl hydrocarbon receptor (AHR) is a ligand-activated receptor and a member of the basic-helix-loop-helix/period/aryl hydrocarbon nuclear translocator-simple-minded (bHLH/PAS) family of transcription factors (Gu et al., 2000) . Members of the bHLH/PAS protein family regulate a wide variety of physiological functions, including circadian rhythms, neurogenesis, cellular response to hypoxia, changes in hormone receptor action, induction of drug-metabolizing enzymes, and xenobiotic detoxification (Gu et al., 2000) . The AHR exhibits profound ligand-binding promiscuity, binding hundreds of environmental toxicants and naturally occurring compounds (Denison and Nagy, 2003) . Ligand binding results in nuclear translocation, heterodimerization with aryl hydrocarbon receptor nuclear translocator (ARNT), and binding of this heterodimer complex to specific AHR response elements (AHREs; or dioxin response elements) (Whitlock, 1999) . Once bound to chromatin, the AHR/ ARNT heterodimer recruits chromatin remodeling complexes and basal transcriptional machinery and initiates transcription of its target genes, including cytochrome P450 1A1 (CYP1A1), CYP1A2 and CYP1B1. Following ligand activation, AHR is exported from the nucleus and is degraded via the 26S proteasome pathway (Pollenz, 2002) . Most of our understanding of AHR signaling is from studying the AHR target genes CYP1A1 and CYP1B1 (Baba et al., 2005; Hankinson, 1995; Poland and Glover, 1974; Whitlock, 1999) . The molecular details regarding ligand-dependent kinetics of AHR recruitment leading to target gene activation and the proteins involved in AHRdependent transcription are not fully understood.
AHR was first identified and characterized as a result of its central role in mediating the toxic effects of dioxins and polycyclic aromatic hydrocarbons (PAHs) such as 2,3,7,8-tetrchlorodibenzo-p-dioxin (TCDD) and 3-methylcholanthrene (3MC), respectively. TCDD is the ligand with the highest affinity for AHR and most, if not all, of its toxic action is mediated through this receptor (Gonzalez and Fernandez-Salguero, 1998) . Despite significant research effort by a number of laboratories, the downstream AHR target genes responsible for TCDDmediated toxicity are not known (Moffat et al., 2007; Puga et al., 2000) . PAHs are ubiquitous environmental contaminants, and activation of AHR by these compounds results in their metabolism through the induction of cytochrome P450 enzymes, namely, CYP1A1 (Nebert et al., 2004) . The stability of TCDD distinguishes it from other readily metabolized AHR activators such as 3MC, phytochemicals, and endogenous compounds (Denison and Nagy, 2003) . It is hypothesized that TCDDmediated toxicities are due to sustained and inappropriate AHR activation leading to the deregulation of important physiological pathways that do not occur with other less stable activators (Bock and Kohle, 2006) .
Recently, our laboratory has reported the TCDD-induced occupancy of AHR to a comprehensive set of human promoter regions using ChIP-chip ). These studies not only identified new genomic targets of AHR but also revealed that many of the AHR-bound genomic regions did not contain an AHRE site. Although ChIP-chip assays are powerful means to identify genomic regions bound by nuclear proteins, it has been reported that a number of parameters including DNA fragmentation, amplification method, choice of antibody, as well as different antibody lots influence the quality of the data (Ponzielli et al., 2008) . We reasoned that if we performed similar ChIP-chip studies that were done to identify TCDD-induced AHR-bound genomic regions but in the presence of a different AHR ligand, the combined and overlapping AHR-bound regions would provide a more robust data set that could be used to further study AHR-dependent transcription. Therefore, in the present study, we examined 3MC-induced recruitment of AHR to human promoter regions in T-47D human breast cancer cells using ChIP-chip. Our results reveal a high degree of overlap between the regions bound by 3MC-activated AHR and TCDDactivated AHR identified by ChIP-chip. Moreover, we provide evidence that 3MC induces gene-selective oscillatory recruitment of AHR and ARNT to target promoters.
MATERIALS AND METHODS
Chemicals. Antibodies used for chromatin immunoprecipitation assays include normal rabbit immunoglobulin (IgG;sc-2027), AHR (H-211), ARNT (H-172) (Santa Cruz Biotechnology, Santa Cruz, CA), histone H3 (ab1791) (Abcam Inc., Cambridge, MA), dimethyl histone H3 lysine 4 (07-030), and acetyl histone H3 lysine 9 (07-352; Millipore, Billerica, MA). The primary antibody used for western blot was AHR (SA-210; Biomol International Inc., Plymouth Meeting, PA). 3MC and dimethyl sulfoxide (DMSO) were purchased from Sigma (St Louis, MO). TCDD was purchased from Accustandard (New Haven, CT). Cell culture media, fetal bovine serum (FBS), and trypsin were all purchased from Invitrogen (Carlsbad, CA). All other chemicals and biochemicals were of the highest quality available from commercial vendors.
Chromatin immunoprecipitation and ChIP-chip experiments. T-47D human breast carcinoma cells from ATCC were cultured in a 1:1 mixture of Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F-12 nutrient mixture medium supplemented with 10% (vol/vol) FBS and 1% penicillin/ streptomycin (PEST) and maintained at 37°C and 5% CO 2 . Forty-eight hours after plating, cells were treated with either 1lM 3MC or DMSO (final concentration 0.1%) for 1 h and ChIP assays were performed as previously described (Matthews et al., 2005) . For ChIP-chip experiments, immunoprecipitated DNA isolated from only the 3MC-treated cells was linearly amplified using a whole genome amplification kit according to the manufacturer's instructions (Sigma). Linearly amplified DNA (7.5 lg) was fragmented by limited DNAseI digestion and hybridized to Affymetrix human promoter tiling arrays 1.0R (Affymetrix, Santa Clara, CA). The hybridization and washing steps were performed according to the manufacturer's protocol at the Center for Applied Genomics (Toronto, Canada). Data were normalized and analyzed using CisGenome and mapped against human genome version hg18 (Ji et al., 2008) . Enriched peaks at a false detection rate (FDR) of 0.2 were determined by comparing triplicate samples of AHR 3MC to triplicate IgG 3MC using a moving average approach with default settings in TileMap v2 (Ji and Wong, 2005) . Regions were merged if the gap between them was < 300 bp and the number of probes failing to reach the cutoff was < 5. Regions were discarded if they were < 120 bp or did not contain at least five continuous probes above the cutoff. For the time course ChIP experiments, T-47D cells were seeded in 10-cm dishes in DMEM:F-12 supplemented with 10% FBS and 1% PEST. After 48 h, cells were treated with 1lM 3MC or 10nM TCDD for 0-4.5 h. For the repeat-dosing ChIP experiments, T-47D cells were treated with 1lM 3MC or DMSO for 1 or 24 h. After the specified time period, the 3MC-treated cells were treated a second time with 1lM 3MC or 10nM TCDD for 0.5 or 1 h. Data were reported as percentages relative to 5% total input chromatin. For histone modification experiments, data were also normalized to total histone H3 content. Quantative PCR (qPCR) primers used to amplify the regions are provided in Supplementary table S1.
Overlap of regions and closest gene definition. The overlap of the identified ChIP regions between the data sets was determined as previously described . Briefly, the AHR regions were clustered so that the regions between the sets overlapping with > 50% of the width of the smallest region were merged. Each region was then labeled with the gene symbol of the closest transcript, regardless of strand, using the all_mRNA and unigene annotation from the University of California Santa Cruz genome browser.
Transcription factor-binding site analysis. We searched for potential transcription factor-binding sites using the motif models from the JASPAR database (Bryne et al., 2008) and the ASAP framework Marstrand et al., 2008) . Briefly, we counted all hits that scored above a threshold t, set to 85% of the total scoring range for a given model as described previously (Wasserman and Sandelin, 2004) . We then performed two types of overrepresentation tests, one using a background and one comparing differences among three data sets (interset test). Specific details about how we dealt with the different lengths of the ChIP regions within data sets have been described elsewhere . We filtered out any transcription factor-binding site that did not have an over-or underrepresentation of at least 3 SDs. The heatmap.2 function in the R gplots() package (Ihaka and Gentleman, 1996) was used to draw the heatmaps.
RNA isolation and Complementary DNA synthesis. T-47D cells were grown in DMEM:F-12 and treated with either 1lM 3MC or DMSO for 1.5, 3, 6, or 24 h. For the re-dose experiments, cells were initially exposed to DMSO, 3MC (1lM), or TCDD (10nM) for 24 h and exposed to the same chemical for an additional 6 h prior to RNA isolation. RNA was isolated using the RNeasy spin columns as per manufacturer's instructions (Qiagen) and reverse transcribed as previously described (Matthews et al., 2005) . qPCR was performed on 1 ll of complementary DNA sample using iQ SYBR Green Supermix (BioRad). All target gene transcripts were run in triplicate and normalized to the ribosomal 18s RNA content, and the expression level of each gene was compared to a timematched DMSO control sample. qPCR primers used to amplify the regions are provided in Supplementary table S2.
Western blot. T-47D cells were plated in 10-cm dishes and treated with 1lM 3MC for 0, 1, 4, or 24 h. Twenty micrograms of protein extract was resolved by SDS/8% polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was blocked overnight in 5% skim milk in PBS at 4°C and immunoblotted with 1:2000 dilution of AHR (SA-210) antibody for 2 h at room temperature. The membrane was then washed for 30 min and incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody for 1 h at room temperature. For detection of b-actin, membranes were stripped prior to immunoblotting with anti-b-actin antibody (Sigma). Proteins were visualized using the ECL Plus Western Blotting Detection Reagents according to the manufacturer's instructions (GE Healthcare).
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RESULTS
Identification of 3MC-Induced AHR-Bound Sites by ChIP-chip
To identify 3MC-induced AHR-bound regions (AHR 3MC ), ChIP-chip assays were performed on T-47D cells treated with 1lM 3MC for 1 h. Chromatin was immunoprecipitated using an anti-AHR (H-211) antibody or rabbit IgG, and the isolated DNA was linearly amplified and hybridized to Affymetrix human 1.0R promoter tiling arrays. Three biological replicates were performed, from which the enriched peaks were identified by comparing triplicate AHR to triplicate IgG samples as described in Materials and Methods section. From our analysis, we identified 241 regions bound by AHR 3MC at an FDR of 0.2 (Fig. 1A) . AHR 3MC regions were referred to as AHR_number, where the number indicates the relative rank within the analysis. A comparison of the AHR 3MC -bound regions to previous ChIPchip experiments from our group that identified AHR-bound genomic regions in TCDD-treated T-47D cells (AHR TCDD ) using the same microarray platform revealed that 127 regions (or 53% of the total number of AHR 3MC regions identified) were common to both data sets (Fig. 1A) . From herein, we will refer to these subsets of regions as the intersect set (regions bound by AHR 3MC and AHR TCDD ), AHR 3MC-only , and AHR TCDD-only . Moreover, 100% of the top 50 and 87% of the top 100 AHR 3MC -bound regions were also bound by AHR TCDD , indicating very good agreement between both ligands in the top-ranked regions. Since each of the isolated regions could be labeled with a target gene, we also assessed the overlap between the AHR 3MC -bound regions and the AHR TCDDbound regions that we have previously reported in terms of target genes. This analysis is not the same as comparing enriched regions, since multiple ChIP regions may be located in the upstream regulatory region of the same gene. The analysis revealed that 56% or 120 putative target genes were common between the AHR 3MC and AHR TCDD data sets (Fig. 1B) . A bed file containing the genomic coordinates for the AHR 3MC -bound regions is provided in Supplementary table S3.
Transcription Factor-Binding Site Analysis of the ChIP
Regions To determine and compare the density of putative transcription factor-binding sites in the AHR 3MC and AHR TCDD regions, we calculated over-or underrepresentation of transcription factor-binding sites compared to a sampled promoter background ( Fig. 2A ). Our analysis showed that 48% (116) of the identified regions contained at least the core AHRE (GCGTG) in the AHR 3MC data set. These findings are in agreement with previous studies showing that~50% of ChIP regions isolated from TCDD-treated mouse hepatoma Hepa1c1c7 cells contained at least the core AHRE (Kinehara et al., 2008) . We then used a Z score statistic to visualize which transcription factor-binding sites were significantly over-and underrepresented by hierarchically clustered heat maps as previously described Liu et al., 2008) , where the rows are the JASPAR database (Bryne et al., 2008) transcription factor-binding sites and the columns are the AHR 3MC or AHR TCDD ChIP-chip data sets. As expected, when compared to a generic promoter sequence background, both the AHR 3MC and AHR TCDD sets had a strong overrepresentation of the AHRE site, represented by the Arnt-Ahr matrix in JASPAR (Fig. 2B ). This was also consistent when assessing overrepresentation between sets, since the intersect set was strongly enriched for AHREs when compared to the AHR 3MC-only or the AHR TCDD-only data sets.
Confirmation of ChIP-chip Regions
To confirm the enriched regions identified by ChIP-chip, conventional ChIPs were performed on a subset of 26 identified regions using qPCR. The regions were chosen to cover a range of enrichment values but also included regions near known AHR-regulated genes. We were able to verify ligand-dependent recruitment of AHR to all 26 regions, with the level of enrichment varying among the regions (Fig. 3) . Some of the identified regions included genomic sequences upstream of CYP1A1 (AHR_103), CYP1B1 (AHR_19), estrogen receptor a (ESR1, AHR_119), gene regulated by estrogen in breast cancer 1 (GREB1, AHR_204), cyclin G2 (CCNG2, AHR_14), forkhead box N4 (FOXN4, AHR_77), sortilin-related receptor (SORL1, AHR_17), inositol 1,4,5-triphosphate receptor, type 1 (AHR_35), retinoblastoma-binding protein 7 (RBBP7, AHR_226), histone deacetylase 11 (HDAC11, AHR_239), and homeobox C10 (HOXC10, AHR_92) genes (see Supplementary table S3 for complete list). We also observed ligand-independent AHR occupancy at the upstream regulatory region of CYP1B1 (AHR_19), which was in agreement with other reports Yang et al., 2008) . Significant ligand-independent AHR occupancy was also observed at the upstream regulatory regions of synaptotagmin XII (AHR_1), transmembrane protein 30A (TMEM30A, AHR_13), pregnancy-specific beta-1-glycoprotein 9 (PSG9, AHR_80), pregnancy-specific beta-1-glycoprotein 5 (PSG5, AHR_142), and GREB1 (AHR_204). 3MC treatment increased AHR occupancy to all the six regions that displayed AHR binding in the absence of ligand. These results were consistent with a previous study from our group ) and may be explained by the observation that AHR can exist simultaneously in the nucleus and cytoplasm in human breast cancer cells (Wang et al., 1998) .
Correlation between 3MC-Induced Chromatin Binding of AHR and Gene Expression
To determine if AHR recruitment to the identified genomic regions resulted in changes in messenger RNA (mRNA) levels of putative target genes, we performed mRNA expression time course analysis of T-47D cells treated with 1lM 3MC or solvent control (DMSO) for 1.5, 3, 6, and 24 h. The mRNA expression of the genes examined varied, ranging from 3MC-dependent increases, decreases, to no change over the time points examined (Table 1) . 3MC treatment increased CYP1A1, CYP1B1, CCNG2, SORL1, and TCDD-inducible poly-ADP-ribose polymerase mRNA expression levels. 3MC treatment caused a slight repression of ESR1 and rat sarcoma-like estrogen-regulated growth inhibitor (AHR_7) mRNA levels at the 1.5-, 6-, and 24-h time points and 1.5-h time point, respectively. No effect of 3MC treatment on GREB1, FOXN4, HDAC11, and transducin (beta)-like 1 X-linked receptor 1 (AHR_99) mRNA levels was observed. These data support previous studies reporting that binding of activated AHR to a given genomic region may not necessarily lead to changes in gene expression Sartor et al., 2009 ).
3MC Induces Oscillatory Recruitment of AHR and ARNT
Ligand-specific oscillatory recruitment of AHR to CYP1A1 and CYP1B1 enhancer regions has been reported for the AHR ligand b-naphthoflavone (Hestermann and Brown, 2003; Wihlen et al., 2009) ; however, such oscillatory recruitment has not been observed or reported for 3MC or TCDD (Hankinson, 2005; Matthews et al., 2005) . Previous studies that investigated ligandinduced and temporal recruitment of AHR focused only on CYP1A1 or CYP1B1 and used a time course ranging from 0 to 165 min. Therefore, it is possible that oscillatory binding of 3MC-or TCDD-bound AHR may exhibit longer and distinct kinetics compared to b-naphthoflavone as well as gene-specific differences. To this end, we performed time course ChIP experiments on T-47D cells treated with 1lM 3MC for 0-4.5 h, and the recruitment of AHR and ARNT was assessed at six different genomic regions. CYP1A1 and CYP1B1 were included in the analysis since they are well-studied AHR target genes. We included ESR1 due to the well-documented cross talk between FIG. 2. Transcription factor-binding site analysis. Heat maps showing the most over-and underrepresented transcription factor-binding site patterns in each set either compared to large promoter background (A) or compared between sets (B). Heat map A can be viewed as an ''absolute'' measure of overrepresentation, while heat map B shows what patterns that are significantly different between at least two sets in terms of occurrence. Over/underrepresentation is expressed as a Z score, where a negative value means underrepresentation and high values indicate overrepresentation (coded white). Z scores were translated into a color range from red to white. Rows (transcription factor-binding patterns from JASPAR) and columns (ChIP regions as in Fig. 1A ) are ordered by similarity to each other. Patterns having no preference to any set are not shown. The Arnt-Ahr pattern, corresponding to an AHRE, is highlighted.
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AHR and estrogen receptor pathways (Matthews et al., 2005; Safe and Wormke, 2003) . CCNG2 was included since it is a negative regulator of cell cycle control. SORL1 is a low-density lipoprotein receptor, and FOXN4 is involved in development, but no mRNA changes in response to 3MC were observed. 3MC treatment induced oscillatory recruitment of AHR and ARNT (Fig. 4) to all the aforementioned 5#-flanking regions. The degree of oscillation varied among the regions analyzed, but in all cases, the highest level of AHR and ARNT promoter occupancy occurred after 0.5 h of treatment. All genes showed a significant reduction in recruitment of AHR and ARNT at the 2-h time point (Fig. 4) . A second peak of AHR and ARNT recruitment was observed between 3.0 and 3.5 h, but the level of AHR or ARNT recruitment did not reach the level obtained after 0.5 h treatment. Cyclical recruitment of AHR and ARNT to CCNG2 was less apparent compared to the other regions examined, whereas a second peak of AHR and ARNT binding to SORL1 was not observed. It should be noted that the same samples were used to test the selected regions and that the observed differences were not due to a lack of immunoprecipitation by the antibodies tested. We also performed time course experiments using cells treated with 10nM TCDD, and similar results were observed at the CYP1A1, CYP1B1, and ESR1 promoter regions (data not shown).
To determine the role of posttranslational histone modifications during oscillatory recruitment of AHR and ARNT, we examined acetylation of lysine 9 (H3K9Ac) and dimethylation of lysine 4 of histone H3 (H3K4Me2) after 1 and 4 h of 3MC treatment (Fig. 5) . These two histone modifications were chosen as they have been associated with activation of AHRmediated transcription (Schnekenburger et al., 2007) : increases in H3K9Ac are associated with increases in transcription, whereas reduction in the level of H3K4Me2 is indicative of transcriptional activation (Kouzarides, 2007) . We observed significant increases in H3K9Ac levels (expressed as a ratio of total H3 content) at CYP1A1, ESR1, CCNG2, SORL1, and FOXN4 5#-flanking regions (Fig. 5 ) after 1 h 3MC treatment. However, only CYP1A1 displayed increased H3K9Ac after 4 h exposure when compared to time-matched solvent controls, and the relative level of H3K9Ac at CYP1A1 was significantly lower than the 1-h time point. No increases in H3K9Ac were observed at CYP1B1 at the time points tested.
In agreement with previous reports, decreased H3K4Me2 was evident at CYP1A1 after 1 and 4 h 3MC treatment, with no significant differences in the relative H3K4Me2 levels between Note. Statistically significant differences compared to time-matched DMSO control samples are indicated by an ''*'' (p < 0.05) or ''**'' (p < 0.01).
FIG. 3.
3MC-induced recruitment of AHR to regions identified by ChIP-chip. Quantification of AHR binding was determined as fold induction above IgG DMSO and is expressed as the mean of three independent replicates. Regions were chosen to cover a range of enrichment values and included a select number of known AHR target genes. T-47D cells were treated with 1lM 3MC for 1 h and ChIP assays were performed with the indicated antibodies. Immunoprecipitated DNA was measured by qPCR using primers targeting regions isolated in the ChIP-chip study. 94 PANSOY ET AL. the two time points. We observed slight, but significant, increases in H3K4Me2 at the CCNG2, ESR1, SORL1, and FOXN4 promoter regions at 1 h, which returned to basal levels after 4 h of 3MC treatment. These findings were surprising for CCNG2 and SORL1, since the mRNA levels of both genes were increased in response to 3MC. No changes in H3K4Me2 were at CYP1B1 were observed.
Repeat Dosing Does Not Influence Binding Kinetics of AHR
Since the time course experiments revealed that peak binding of AHR and ARNT occurred after 0.5 h exposure to 3MC with a second peak occurring after 3-3.5 h (Fig. 4) , we wanted to determine if a repeat dosing of cells already exposed to 3MC for 1 h could prolong or alter the kinetics of AHR/ ARNT binding to the 5#-flanking regions of the abovementioned genes. Therefore, we re-treated cells with 1lM 3MC for 0.5 or 1 h after an initial 1 h pretreatment with ligand. Interestingly, 3MC re-treatment did not result in a prolonged peak of AHR and ARNT recruitment, but rather the binding profiles of both factors were unaffected resulting in a significant decrease in transcription factor occupancy when compared to the recruitment level at 1 h (Fig. 6) . Cells initially treated with 3MC for 1 or 3 h and then re-dosed with TCDD also failed to induce increased AHR recruitment to the target promoters examined (data not shown). We then performed a similar experiment in which we treated cells with 3MC for 24 h and then re-dosed the cells for 0.5 h without replenishing the media. In this case, we observed a significant increase in AHR and ARNT recruitment to the 5#-flanking regions after the 0.5-h re-dose, with the exception of SORL1 where there was significant recruitment of AHR only after the re-dose (Fig. 7A) . In contrast, treatment with TCDD resulted in no significant difference between the 24-and 24 þ 0.5-h re-dose time points for AHR and ARNT recruitment (Fig. 7A) . Western blots were performed on T-47D cells treated with 1lM 3MC for 0, 1, 4, and 24 h to confirm endogenous AHR protein expression (Fig. 7B) . As expected, we observed that ligand activation of AHR induces its proteolytic degradation (Pollenz and Buggy, 2006) (Fig. 7B) . The increased degradation supports the reduced recruitment levels of AHR observed after 24 h. Membranes were stripped and incubated with anti-b-actin antibody verifying equivalent protein loading at all time points examined.
To determine if the re-dosing effects on 3MC-and TCDDinduced recruitment of AHR to its target genes also correlated with changes in mRNA expression levels, we determined the mRNA expression levels of six AHR target genes after 24 h treatment with 3MC or TCDD and compared with those determined after a repeat dosing with the same ligand for an additional 6 h. The data shown in Figure 8 reveal that repeat treatment with 3MC after an initial dosing of 24 h resulted in significant increases in five out of the six gene products examined, whereas repeat treatment with TCDD had no effect on mRNA expression levels compared to a single 24-h treatment. Interestingly, repeat treatment with 3MC had no additional inhibitory effect on ESR1 mRNA levels. In contrast, an additional 6-h treatment of TCDD following 24 h exposure resulted in a slight but significant increase in ESR1 mRNA levels.
DISCUSSION
In this study, we used promoter-focused human tiling arrays to identify genomic regions bound by AHR in response to 3MC treatment of T-47D human breast carcinoma cells. A comparison of the AHR 3MC -bound regions to ChIP-chip data obtained for AHR TCDD -bound regions (Ahmed et al., FIG. 4 . 3MC induces oscillatory recruitment of AHR and ARNT. T-47D cells were treated with 1lM 3MC for 0-4.5 h, and ChIP assays were performed with specific antibodies against IgG, AHR, and ARNT. Immunoprecipitated DNA was measured by qPCR using primers for a subset of regions isolated in the ChIPchip study. Data are represented as percent recruitment relative to 5% chromatin input and represent the mean of two independent replicates in which the SEM was less than 5%. For simplicity, IgG recruitment was not shown, as it was less than 0.5% for all genes tested. All ChIPs were performed from a single chromatin preparation for each time point.
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2009) revealed a good degree of overlap between the data sets (53%). While the functional significance of AHR recruitment to the identified genes and the role that each of the potential target genes play in AHR-mediated signaling remains to be fully investigated, the identified target regions add to the growing list of target genes that may contribute to biological effects caused by exposure to these chemicals.
Comparison of our AHR 3MC ChIP-chip results to those recently reported by Sartor et al. (2009) using Hepa1 mouse hepatoma cells treated with benzo[a]pyrene (B[a]P) revealed that only 9 of the 750 AHR B[a]P -bound regions that the authors' reported in their study were present in our data set (Sartor et al., 2009) . The low degree of overlap could be attributed to cell type, species (mouse hepatoma vs. human breast carcinoma), and ligand differences. However, when we compared the identified AHR B[a]P or AHR TCDD genes reported by Sartor et al. (2009) to AHR-bound regions identified from ChIP combined with highthroughput southwestern chemistry-based ELISA using TCDDtreated mouse hepatoma cells (Kinehara et al., 2008) , we also found very low overlap in the identified AHR target genes (four for AHR B[a]P and five for AHR TCDD ). These findings suggest that variations in the ChIP methodologies among different laboratories contribute to the low degree of overlap in AHRregulated regions among the studies. Future ChIP-chip or ChIPSeq studies will need to be performed in a number of different cell lines and tissues from experimental animal models using standardized and validated methodologies in order to determine the battery of genes regulated by AHR.
Although traditionally thought to exist in the cytoplasm, growing evidence indicates that the AHR may exist in a continued state of nucleocytoplasmic shuttling (Song and Pollenz, 2002) . AHR has recently been reported to occupy a significant number of its target promoters and actively participates in the regulation of many of these genes in unstimulated cells (Sartor et al., 2009) . Promoter occupancy of a constitutively active AHR to the 5#-flanking region of c-Myc was found to influence the expression of the c-Myc oncogene in Hs578T human breast cancer cells (Yang et al., 2005) . Our experimental setup for the ChIP-chip did not allow us to determine the occupancy of AHR in unstimulated cells. However, our ChIP results revealed AHR occupancy to 6 of 26 promoter regions in unstimulated cells. In all cases, AHR occupancy was increased FIG. 5. 3MC induces gene-specific changes in histone H3 acetylation and methylation. T-47D cells were treated with 1lM 3MC or DMSO for 1 and 4 h. ChIP assays were performed with specific antibodies against IgG, H3, H3K4Me2, and H3K9Ac. Immunoprecipitated DNA was measured by qPCR using primers for a subset of regions isolated in the ChIP-chip study. Data are represented as relative histone modification H3K4Me2 (A) and H3K9Ac (B) relative to total H3 detected ± SEM. A representative replicate is shown. Asterisks indicate statistically significant differences (p < 0.05) when compared to DMSO. Relative modification level significantly different (p < 0.05) when compared to 1 h are denoted with a dagger sign.
96 PANSOY ET AL. with the addition of agonist, suggesting that for certain AHR target promoters the receptor is bound to the promoter region in the unstimulated cells.
Transcription factor-binding analysis demonstrated that AHREs were highly enriched in the AHR 3MC data set; however, about half of the regions did not contain the AHRE core FIG. 6 . Repeat 3MC treatment fails to induce increased recruitment of AHR and ARNT to its target genes. T-47D cells were pretreated with 1lM 3MC and then re-dosed with 1lM 3MC for 0.5 or 1 h. ChIP assays were performed with the indicated antibodies, and immunoprecipitated DNA was measured by qPCR using primers targeting regions isolated in the ChIP-chip study. Data are represented as percent recruitment relative to 5% chromatin input and represent the mean of two independent replicates. For simplicity, IgG recruitment was not shown, as it was less than 0.5% for all genes tested. Asterisks indicate statistically significant differences (p < 0.05) when compared to DMSO recruitment levels. Recruitment levels significantly different (p < 0.05) when compared to recruitment levels at 1lM 3MC for 1 h are denoted with a dagger sign.
FIG. 7.
Repeat dosing with 3MC but not to TCDD increases recruitment of AHR to its target genes after 24 h of pretreatment with ligand. (A) T-47D cells were pretreated with 1lM 3MC or 10nM of TCDD for 24 h and then re-dosed with 1lM 3MC or 10nM TCDD for 0.5 h. ChIP assays were performed with the indicated antibodies, and immunoprecipitated DNA was measured by qPCR using primers targeting regions isolated in the ChIP-chip study. Data are represented as percent recruitment relative to 5% chromatin input and represent the mean of two independent replicates. For simplicity, IgG recruitment was not shown, as it was less than 0.5% for all genes tested. Asterisks indicate statistically significant differences (p < 0.05) when compared to DMSO recruitment levels. Recruitment levels significantly different (p < 0.05) when compared to recruitment levels at 24 h are denoted with a dagger sign. (B) T-47D cells were treated with 1lM 3MC for 0-24 h, and protein extracts were probed with specific antibodies to confirm endogenous AHR protein expression. AHR (96 kDa) was detected at all time points. Protein extracts were also probed with an antibody specific for b-actin, and the detected bands at 42 kDa were of similar intensity, indicating equivalent protein loading.
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(GCGTG) sequence. This is consistent with other studies reporting AHR binding to genomic regions that did not contain an AHRE Kinehara et al., 2008) and suggests that AHR might exhibit greater DNA-binding promiscuity. In support of this notion, AHR has been reported to regulate gene expression through an AHRE-like sequence (GCGGG) (Gouedard et al., 2004) and also through tethering to other transcription factors (Marlowe et al., 2004) , which cannot be distinguished from direct DNA binding of AHR using the ChIP assay. We have only used a promoter-focused array, and thus, we cannot exclude the possibility that other AHREcontaining sequences that are not present on the arrays which may be bound by AHR (i.e., AHR occupancy at regions proximal to promoters) are involved in the regulation of the target regions that did not contain a core AHRE. However, de novo sequence analysis of the 127 regions that were in common between AHR 3MC and AHR TCDD data sets identified an AHRE site (Pansoy and Matthews, unpublished data) . The AHR-bound regions identified from this study can be further interrogated to uncover new insight into AHR-binding preferences.
Our group and others have reported temporal recruitment of AHR and associated factors to CYP1A1 with b-naphthoflavone using a shorter time course (0-2.5 h) (Hestermann and Brown, 2003; Wihlen et al., 2009) . By extending our time course to 4.5 h, we were surprised to observe a well-defined oscillatory recruitment of AHR and ARNT for both 3MC and TCDD to some, but not all, of the AHR-bound regions analyzed. However, high level of recruitment of AHR or ARNT was observed at all genes after approximately 0.5-1.0 h treatment. The main difference among the genes was the magnitude and/ or presence of a second binding peak that occurred around 3-3.5 h for CYP1A1. This suggests that AHR exhibits preferential promoter binding after prolonged ligand activation. The biological relevance of the oscillatory binding of ligandactivated AHR to its target genes remains to be determined. Although we have observed a similar oscillatory recruitment of AHR and ARNT in MCF-7 human breast cancer cells, such temporal recruitment patterns were not observed in Hepa1 mouse hepatoma cells, commonly used in AHR signaling work, treated with 3MC or TCDD (data not shown). However, our data highlight distinct kinetic differences in AHR recruitment to its target genes and that the choice of time point may greatly influence the amount of AHR present at different target genes.
We also examined whether changes in histone H3K9Ac or HeK4Me were associated with the differential oscillatory recruitment of AHR and ARNT to their target gene promoters. Although no clear correlation between histone H3 modifications and oscillatory binding of AHR or ARNT was evident, notable differences in the histone modification patterns at the different genes were observed. For example, increased H3K9Ac was observed at CYP1A1 but not at CYP1B1. In agreement with previous reports, we also observed a 3MC-dependent decrease in H3K4Me at CYP1A1; however, no changes in H3K4Me were observed at CYP1B1. These findings support other work that has identified differential recruitment of chromatin-modifying factors to CYP1A1 and CYP1B1 (Taylor et al., 2009) . Surprisingly, we observed increased H3K4Me at CCNG2 despite observing increased mRNA expression of this gene product following 3MC treatment.
We also report that treating cells with a second dose of 3MC following an initial dose of 3MC for 1 h failed to alter the peak of AHR and ARNT recruitment. These observations suggest that agonists activate a wave of receptors and that this activation is FIG. 8 . Repeat dosing with 3MC but not TCDD results in changes in mRNA expression levels of AHR target genes. T-47D cells were treated with DMSO, 3MC (1lM), or TCDD (10nM) for 24 h only or were re-dosed with each of the ligands for an additional 6 h. RNA was isolated and reverse transcribed after treatment. The determination of mRNA expression levels was done by qPCR. Data are represented as mRNA expression normalized against time-matched DMSO and to ribosomal 18s levels ± SEM. A representative replicate is shown. Asterisks indicate statistically significant differences (p < 0.05) when compared to 24-h treatment samples. 98 PANSOY ET AL.
followed to completion before the gene can become responsive to AHR ligands. Furthermore, this effect cannot be abolished when re-dosing with a more potent ligand such as TCDD. It was only after 24 h that many of the target genes became responsive to second dose of 3MC. Despite observing~90% degradation of AHR following 24 h ligand treatment, a second 1-h dose of 3MC induced an increased recruitment of AHR to its target promoter regions in a manner similar to that observed after single 1-h dose of 3MC. This suggests that only a small pool of AHR is recruited to target promoter regions following AHR and supports the presence of ''spare'' receptors in AHR activation (Hestermann et al., 2000) . We did not observe any further increase in AHR or ARNT recruitment after a 0.5-h dose of cells treated with TCDD for 24 h. Our 24-h mRNA re-dose data also show that re-exposing cells to 3MC for an additional 6 h causes a significant increase in gene transcription, whereas TCDD treatment does not. These differences are likely due to the differences in metabolism between the two compounds with 3MC being metabolized much more rapidly than the very stable TCDD (Riddick et al., 1994) . TCDD binding results in a prolonged association with the receptor and thus maintains the receptor in an active form for longer periods compared to 3MC. It has been proposed that TCDD toxicity is a result of the stability of TCDD and thus a prolonged activation of AHR target genes (Bock and Kohle, 2006) .
The results of our study provide new insight into the 3MC-mediated chromatin-binding profiles of AHR and ARNT through the identification of genomic regions bound by AHR and target genes regulated by this receptor. We also demonstrate that 3MC induces oscillatory recruitment of AHR and ARNT in a gene-selective manner, and this oscillatory binding was unaffected by repeat treatment with ligand. Finally, we show that T-47D cells became responsive to 3MC but not TCDD after an initial 24 h of exposure to 3MC, highlighting important differences in AHR responsiveness between the two ligands, which may contribute to the different toxicities elicited by them. It should be noted that the observed cyclical binding of AHR to its target promoters and the target genes identified here may be limited to certain human breast carcinoma cells in culture, so it is important to extend this analysis to nontumorigenic breast cells and other human cell lines.
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